Tekla Life Sciences Investors -Benef.Int.- (257689

Closed-end funds have unique features that make them very attractive investment vehicles for the right asset classes and investors who understand them. Especially for complex and/or less liquid asset classes, like corporate senior loans, high-yield bonds, collateralized loan obligations, and the more recently discovered (by retail investors) "private credit" Activist and institutional investors are worth watching, so we can piggyback onto their efforts in the closed-end fund world. » Mehr auf seekingalpha.com

For the second consecutive month, both equity (+3.42% on a NAV basis) and fixed income (+3.14%) CEFs on average posted plus-side returns. At month end, 9% of all CEFs traded at a premium to their NAV, with 9% of equity CEFs and 8% of fixed income CEFs trading in premium territory. Developed Markets CEFs (+6.45%), for the second straight month, outpaced the other classifications in the equity CEF universe for December. » Mehr auf seekingalpha.com

Tekla Life Sciences Investors invests primarily in biotechnology stocks, and 10-12 large-cap biotech stocks (50% of total holdings) sets the trend and price direction for this fund. Poor price growth of biotech stocks thus has resulted in a huge price loss for this fund. However, the HQL closed-end fund has delivered consistent strong yields over the years. Despite poor price growth, I am bullish about the biotech sector due to aging demographics, adoption of new medical products, and robust M&A activities. » Mehr auf seekingalpha.com